BioLife Secures U.S. Patent for First-of-its-kind Effervescent Oral Peptide Delivery Technology

Contributed by: Business Wire

Logo

Business Wire logo

Images

BioLife offers a new solution for oral GLP-1 delivery
BioLife offers a new solution for oral GLP-1 delivery
Business Wire embedded0

Tags

Science
Other Science
Research
Pharmaceutical
General Health
Health
Diabetes
Clinical Trials
BioLife

More Like This

BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

Landmark Medicines Advances Proprietary Nasal GLP-1 Platform Towards Human Evaluation

ACCESSWIRE logo

Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-1

Over 55,000 people already on Simple Online Healthcare's waitlist for UK's first, newly approved oral GLP-1

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing

First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA